Prothena Corporation plc (PRTA) concluded trading on Wednesday at a closing price of $5.75, with 4.97 million shares of worth about $28.59 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.04% during that period and on June 18, 2025 the price saw a gain of about 0.88%. Currently the company’s common shares owned by public are about 53.83M shares, out of which, 42.32M shares are available for trading.
Stock saw a price change of 12.75% in past 5 days and over the past one month there was a price change of -22.30%. Year-to-date (YTD), PRTA shares are showing a performance of -58.48% which decreased to -71.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.32 but also hit the highest price of $25.42 during that period. The average intraday trading volume for Prothena Corporation plc shares is 1.45 million. The stock is currently trading 8.36% above its 20-day simple moving average (SMA20), while that difference is down -21.50% for SMA50 and it goes to -57.74% lower than SMA200.
Prothena Corporation plc (NASDAQ: PRTA) currently have 53.83M outstanding shares and institutions hold larger chunk of about 70.13% of that.
The stock has a current market capitalization of $309.51M and its 3Y-monthly beta is at -0.08. It has posted earnings per share of -$2.08 in the same period. It has Quick Ratio of 9.00 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRTA, volatility over the week remained 5.12% while standing at 9.08% over the month.
Analysts are in expectations that Prothena Corporation plc (PRTA) stock would likely to be making an EPS of -1.2 in the current quarter, while forecast for next quarter EPS is -0.84 and it is -2.71 for next year. For the current quarter EPS, analysts have given the company a lowest target -2.57 which is -0.5 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 1.22 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -67.65% while it is estimated to increase by 29.61% in next year. EPS is likely to shrink at an annualized rate of -9.84% for next 5-years, compared to annual growth of -3.15% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on May 28, 2025 offering an Underperform rating for the stock and assigned a target price of $4 to it. Stock get a Buy rating from Chardan Capital Markets on December 20, 2024.
